PMAM
TXMD icon

Picton Mahoney Asset Management’s TherapeuticsMD TXMD Stock Holding History

Picton Mahoney Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-66
Closed -$15K – 361
2014
Q4 		$15K Buy
+66
New +$13.6K ﹤0.01% 301

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Picton Mahoney Asset Management's TXMD Position: Q1 2015 in Review

Picton Mahoney Asset Management sold out of TherapeuticsMD (TXMD) in Q1 2015, closing a stake of 66 shares — an estimated $15K sold.

Picton Mahoney Asset Management first reported a position in TXMD in Q4 2014 and held it in 1 quarter. The position peaked at $15K in Q4 2014. 94 funds tracked by Wall St. Rank hold TXMD as of Q1 2015.

  • Picton Mahoney Asset Management reported no remaining TherapeuticsMD position as of Q1 2015 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 66 TherapeuticsMD shares in Q1 2015, an estimated $15K.
  • Picton Mahoney Asset Management first reported a position in TherapeuticsMD in Q4 2014 and held it in 1 quarter.
  • Picton Mahoney Asset Management's TherapeuticsMD position peaked at $15K in Q4 2014.
  • 94 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2015.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2015, filed 29 Apr 2015.